VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
VRTX on Nasdaq
Shares outstanding
254,691,824
Price per share
$438.92
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
232,410,626
Total reported value
$105,318,978,355
% of total 13F portfolios
0.04%
Share change
+2,473,112
Value change
+$1,259,001,970
Number of holders
1,598
Price from insider filings
$438.92
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Capital World Investors 11% $14,470,577,412 28,739,975 Capital World Investors 31 Dec 2024
Capital Research Global Investors 6.8% +18% $7,976,978,476 +$1,281,683,793 17,319,044 +19% Capital Research Global Investors 31 Dec 2025
FMR LLC 3.6% $4,642,686,284 9,220,827 FMR LLC 31 Dec 2024

As of 31 Dec 2025, 1,598 institutional investors reported holding 232,410,626 shares of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX). This represents 91% of the company’s total 254,691,824 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) together control 66% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Capital World Investors 10% 25,510,182 -1.5% 1.6% $11,565,309,006
VANGUARD GROUP INC 9.5% 24,105,823 -0.46% 0.16% $10,928,615,915
BlackRock, Inc. 9.3% 23,751,989 +6.7% 0.18% $10,768,201,653
Capital Research Global Investors 6.8% 17,316,344 +4.6% 1.4% $7,850,543,946
STATE STREET CORP 4.6% 11,689,539 +0.72% 0.18% $5,299,569,401
JPMORGAN CHASE & CO 2.4% 6,039,481 -6.1% 0.18% $2,738,059,237
GEODE CAPITAL MANAGEMENT, LLC 2.3% 5,981,905 +0.14% 0.17% $2,700,207,827
Capital International Investors 1.9% 4,733,596 +0.95% 0.34% $2,146,040,530
ALLIANCEBERNSTEIN L.P. 1.8% 4,496,482 -0.58% 0.64% $2,038,525,080
LOOMIS SAYLES & CO L P 1.6% 4,033,525 -2.1% 2.2% $1,828,638,685
WELLINGTON MANAGEMENT GROUP LLP 1.5% 3,821,731 -20% 0.3% $1,732,619,966
VICTORY CAPITAL MANAGEMENT INC 1.3% 3,356,766 +49% 0.86% $1,521,850,963
JENNISON ASSOCIATES LLC 1.3% 3,249,541 -5.9% 0.88% $1,473,211,801
NORGES BANK 1.2% 3,176,613 0.15% $1,440,149,270
MORGAN STANLEY 1.2% 3,120,310 +0.38% 0.08% $1,414,625,263
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 1.2% 3,000,778 +3.9% 0.29% $1,360,432,714
BANK OF AMERICA CORP /DE/ 1.2% 2,937,030 +3.4% 0.1% $1,331,532,113
Clearbridge Investments, LLC 1.1% 2,860,176 +8.1% 1% $1,296,689,269
NORTHERN TRUST CORP 1% 2,579,457 -1.8% 0.15% $1,169,422,624
PRICE T ROWE ASSOCIATES INC /MD/ 0.89% 2,278,958 -25% 0.11% $1,033,189,000
AMERIPRISE FINANCIAL INC 0.89% 2,263,732 -0.58% 0.23% $1,026,286,730
JANUS HENDERSON GROUP PLC 0.87% 2,221,953 +4.9% 0.45% $1,007,381,334
FMR LLC 0.87% 2,212,596 -33% 0.05% $1,003,101,845
Legal & General Group Plc 0.77% 1,970,105 +0.91% 0.2% $893,166,805
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.73% 1,859,221 +1.6% 0.13% $842,896,433

Institutional Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 232,410,626 $105,318,978,355 +$1,259,001,970 $453.36 1,598
2025 Q3 231,845,271 $90,712,303,749 -$3,681,734,988 $391.64 1,505
2025 Q2 240,735,835 $107,165,642,790 +$1,856,744,900 $445.20 1,543
2025 Q1 236,653,399 $114,743,267,144 +$569,969,794 $484.82 1,597
2024 Q4 236,056,630 $95,094,515,159 +$124,454,808 $402.70 1,542
2024 Q3 234,301,041 $108,951,765,309 -$108,863,209 $465.08 1,532
2024 Q2 234,132,938 $109,741,428,164 +$127,466,437 $468.72 1,538
2024 Q1 233,778,905 $97,614,728,920 -$351,588,308 $418.01 1,481
2023 Q4 234,732,281 $95,518,842,840 -$282,404,031 $406.89 1,430
2023 Q3 235,201,359 $81,839,440,920 -$491,731,898 $347.74 1,268
2023 Q2 236,903,503 $83,231,226,220 -$329,673,784 $351.91 1,270
2023 Q1 237,449,022 $74,800,726,409 +$551,796,768 $315.07 1,191
2022 Q4 237,264,020 $68,520,934,164 +$69,172,686 $288.78 1,206
2022 Q3 237,170,581 $68,704,605,708 +$746,235,756 $289.54 1,108
2022 Q2 234,049,687 $65,932,675,845 +$619,489,758 $281.79 1,093
2022 Q1 233,557,250 $60,872,369,529 +$1,115,223,036 $260.97 1,050
2021 Q4 229,577,277 $50,395,687,889 -$237,458,680 $219.60 1,015
2021 Q3 230,800,835 $41,840,598,359 -$222,800,189 $181.39 920
2021 Q2 232,062,084 $46,728,254,072 -$411,655,570 $201.63 961
2021 Q1 235,696,332 $50,611,371,510 -$676,555,551 $214.89 983
2020 Q4 238,859,796 $56,374,238,590 -$907,518,096 $236.34 952
2020 Q3 242,062,493 $65,824,669,920 -$146,259,561 $272.12 931
2020 Q2 242,428,011 $70,341,346,452 -$453,115,099 $290.31 949
2020 Q1 244,182,755 $58,075,410,564 +$196,877,946 $237.95 842
2019 Q4 243,469,587 $53,307,090,832 -$548,123,974 $218.95 801
2019 Q3 245,828,310 $41,645,081,563 +$11,091,504 $169.42 696
2019 Q2 245,761,916 $45,037,488,806 +$697,671,100 $183.38 706
2019 Q1 245,359,778 $45,126,400,894 +$339,461,201 $183.95 727
2018 Q4 243,404,158 $40,329,522,766 +$325,902,984 $165.71 690
2018 Q3 241,051,774 $46,450,620,394 +$73,088,499 $192.74 687
2018 Q2 241,039,338 $40,950,724,377 +$46,743,521 $169.96 682
2018 Q1 240,511,936 $39,191,663,333 +$165,476,417 $162.98 674
2017 Q4 239,681,066 $35,912,095,840 +$288,569,706 $149.86 637
2017 Q3 237,711,534 $36,110,677,595 +$313,167,858 $152.04 605
2017 Q2 236,016,217 $30,400,623,804 +$78,079,742 $128.87 569
2017 Q1 235,865,728 $25,790,913,428 +$2,166,564,931 $109.35 512
2016 Q4 236,349,218 $17,416,160,042 -$346,305,205 $73.67 470
2016 Q3 240,883,461 $20,998,584,687 +$86,246,858 $87.21 480
2016 Q2 239,982,115 $20,645,253,416 +$255,018,558 $86.02 473
2016 Q1 236,595,476 $18,805,795,173 -$180,672,437 $79.49 487
2015 Q4 234,502,647 $29,506,588,526 -$17,291,028 $125.83 510
2015 Q3 235,203,508 $24,493,775,645 +$667,231,333 $104.14 487
2015 Q2 230,096,138 $28,415,941,068 -$406,870,829 $123.48 496
2015 Q1 233,389,366 $27,539,570,108 +$443,200,071 $117.97 471
2014 Q4 229,712,105 $27,292,739,520 -$488,784,588 $118.80 467
2014 Q3 233,322,706 $26,203,942,928 +$763,613,344 $112.31 424
2014 Q2 227,000,681 $21,491,265,738 +$278,089,765 $94.68 405
2014 Q1 223,473,017 $15,797,763,300 +$100,431,175 $70.72 390